Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dogwood Therapeutics, Inc.DWTX · Entity 6845 | Director | June 16, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dogwood Therapeutics, Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2036-06-16 | Direct | 16,800 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 16,800 · Balance 16,800 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 17, 2026 17:16 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 16,800 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001825986-26-000002 · form4-06172026_050656.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2036-06-16 Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 17:58 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 2,362 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001415889-25-018640 · form4-07012025_050707.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,362 Underlying: Common Stock · 2,362 shares Expires 2035-06-27 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 16:02 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 210 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001415889-25-017938 · form4-06232025_040645.xml · derivative · entry 2 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420 Underlying: Common Stock · 210 shares Expires 2035-06-18 Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 16:02 UTC | Dogwood Therapeutics, Inc. DWTX · Entity 6845 | GrantStock Option (right to buy) · Derivative | 210 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001415889-25-017938 · form4-06232025_040645.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210 Underlying: Common Stock · 210 shares Expires 2035-06-18 Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 18:01 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 4,709 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-24-005679 · form4-02282024_060230.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,709 Underlying: Common Stock · 4,709 shares Expires 2034-02-26 F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 18:06 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001415889-23-009993 · form4-06202023_060614.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option will vest 100% on June 15, 2024, one year following the grant date. Read SEC document |
| June 23, 2022 Filed Jun 30, 2022 18:03 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001415889-22-007089 · form4-06302022_110615.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2032-06-23 F1 · derivative.exercise_date: The stock option will vest 100% on June 23, 2023, one year following the grant date. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 20:12 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | PurchaseCommon Stock | 5,000 | $5.80 | $28,975.00 |
DisclosureSEC source: 0001415889-22-000350 · form4-01052022_120151.xml · nonDerivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.75 to $5.80, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 18:48 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | GrantStock Option (right to buy) · Derivative | 7,875 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-21-003150 · form4-06232021_110655.xml · derivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 7,875 shares Expires 2031-06-22 F1 · derivative.exercise_date: The stock option will vest in 12 equal monthly installments following the grant date. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 1,602 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-21-010383 · tm214953-1_4seq1.xml · derivative · entry 2 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ethica Group, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,602 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: The Reporting Person provided notice of exercise to the Issuer on January 20, 2021 and the Company authorized the issuance of the shares pursuant to such exercise on January 28, 2020. F1 · ownership.nature: The securities are owned directly by Ethica Group, LLC ("Ethica"), the Reporting Person is managing member of Ethica and may be deemed to beneficially own the securities held directly by Ethica. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 00:54 UTC | Dogwood Therapeutics, Inc. VIRI · Entity 6845 | Exercise / conversionCommon Stock | 1,602 | $7.80 | $12,495.60 |
DisclosureSEC source: 0001104659-21-010383 · tm214953-1_4seq1.xml · nonDerivative · entry 1 Keefer David R · CIK 0001825986 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ethica Group, LLC Disclosed balance after: 7,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities are owned directly by Ethica Group, LLC ("Ethica"), the Reporting Person is managing member of Ethica and may be deemed to beneficially own the securities held directly by Ethica. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.